Biocon Biologics launches product for autoimmune diseases in Australia

 23 Jul 2025 12:20 PM

Biocon's subsidiary, Biocon Biologics, has introduced Nepexto, a biosimilar to Enbrel (Etanercept), in Australia for treating autoimmune diseases like rheumatoid arthritis. Marketed through Generic Health, Nepexto aims to broaden patient access in the country.

Biocon: Biocon Biologics Unveils Nepexto®, A Biosimilar to Enbrel® (Etanercept) in Australia 🇦🇺💉

 23 Jul 2025 09:16 AM

Biocon: Biocon Biologics Unveils Nepexto®, A Biosimilar to Enbrel® (Etanercept) in Australia 🇦🇺💉

Biocon, Dalmia Bharat among 10 stocks hitting new 52-week high; surge up to 25% in a month

 18 Jul 2025 05:53 PM

Despite a 501-point Sensex drop, 10 BSE 500 stocks hit fresh 52-week highs, showing strong momentum and investor confidence. Gains ranged from 9% to 26% over the past month.

Breakout Stocks: How to trade Biocon, RBL Bank & HDFC AMC that hit fresh 52-week high?

 16 Jul 2025 10:24 PM

Indian market closed with a positive bias, as BSE Sensex and Nifty50 saw gains, led by auto, FMCG, realty, and IT sectors. Biocon, RBL Bank, and HDFC AMC hit fresh 52-week highs. Analysts suggest monitoring Biocon for a breakout above 425, RBL Bank for profit-booking, and HDFC AMC's bullish trend with resistance at 5,453.

Biocon among 11 stocks hitting 52-week high, rally up to 20% in a month

 16 Jul 2025 06:26 PM

Sensex edged up 63 points, while 11 BSE 500 stocks hit 52-week highs, including Biocon, HDFC AMC, and Nippon Life, signaling strong momentum and bullish sentiment across key sectors.

Biocon plans to launch generic Wegovy obesity drug in India by 2027, CEO says

 16 Jul 2025 04:06 PM

Biocon is set to launch generic versions of Wegovy in India and Canada, aiming for market entry by late 2026 or early 2027. This strategic move targets the rapidly expanding weight-loss drug market, projected to reach $150 billion globally. The company is also planning filings in other emerging markets and seeking local partnerships for commercialization.

Biocon Biologics gets USFDA nod for diabetes medication

 16 Jul 2025 11:07 AM

Biocon Biologics has secured USFDA approval for Kirsty. Kirsty is an interchangeable biosimilar to NovoLog, used for diabetes treatment. It is a rapid-acting insulin analog. The medication will be available in prefilled pens and vials. This approval expands Biocon's insulin portfolio. Kirsty has been available in Europe and Canada since 2022. The US market for Insulin Aspart is significant.

Biocon shares surge 3% as subsidiary obtains USFDA approval for diabetes drug

 16 Jul 2025 09:54 AM

Biocon share price jumped after its subsidiary Biocon Biologics received USFDA approval for Kirsty, a rapid-acting insulin biosimilar. This makes it the first interchangeable version of NovoLog in the U.S., expanding Biocon’s insulin portfolio amid a growing diabetes burden in the country.

Biocon: Biocon Biologics Grows Diabetes Product Line After FDA Approves Kirsty™, The Unique Rapid-Acting Insulin Aspart In The U.S. 🇺🇸💉

 16 Jul 2025 07:03 AM

Biocon: Biocon Biologics Grows Diabetes Product Line After FDA Approves Kirsty™, The Unique Rapid-Acting Insulin Aspart In The U.S. 🇺🇸💉

Stocks to buy or sell today: Biocon, Voltas among 7 trading ideas for 15 July 2025

 15 Jul 2025 09:44 AM

Indian market is expected to consolidate, mirroring mixed global signals, with Nifty futures closing negatively. Option data indicates a trading range between 24,600 and 25,600. Experts recommend buying Biocon, LIC Housing Finance, Marico, Prestige Estates, Ambuja Cements, and Voltas, while suggesting selling Tata Motors for short-term gains.